

eTable 1. Patient characteristics grouped by second line treatment.

	2nd relapse treatment		p-value
	None (n = 14)	PLEX/AD (n = 19)	
Age	53 (13)	44 (18)	0.10
Sex			
Female	12 (86%)	16 (84%)	
Male	2 (14%)	3 (16%)	
Disease duration (y)	4 (9)	3 (5)	0.29
Maintenance treatment before			0.72
None	7 (54%)	12 (63%)	
Treatment	6 (46%)	7 (37%)	
Onset			0.29
First onset	4 (29%)	10 (53%)	
Ongoing disease	10 (71%)	9 (47%)	
Days to C5 inhibition	13 (7)	25 (13)	0.001
EDSS prior to relapse	0 (0, 3.0)	0 (0, 2.0)	0.65
EDSS at relapse	3.25 (3.0, 4.0)	6.5 (5.0, 8.0)	0.006
EDSS at nadir	3.25 (3.0, 4.0)	8.0 (6.5, 8.5)	<0.001
EDSS at 1-3m follow-up	3.0 (2.0, 3.5)	6.0 (3.0, 7.5)	0.007
EDSS at 6m follow-up	2.0 (0.0, 3.0)	2.75 (2.0, 6.5)	0.19
Leading symptom			0.040
Myelitis	5 (36%)	14 (74%)	
Other	9 (64%)	5 (26%)	
Leading symptom			
ON	8 (57%)	2 (11%)	
Other	6 (43%)	17 (89%)	
Symptoms			
Multiple	2 (14%)	8 (42%)	
Single	12 (86%)	11 (58%)	